RT Journal Article
SR Electronic
T1 Humoral and cellular immune responses against SARS-CoV-2 variants and human coronaviruses after single BNT162b2 vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.16.21255412
DO 10.1101/2021.04.16.21255412
A1 Stankov, Metodi V.
A1 Cossmann, Anne
A1 Bonifacius, Agnes
A1 Dopfer-Jablonka, Alexandra
A1 Ramos, Gema Morillas
A1 Gödecke, Nina
A1 Scharff, Anna Zychlinsky
A1 Happle, Christine
A1 Boeck, Anna-Lena
A1 Tran, Anh Thu
A1 Pink, Isabell
A1 Hoeper, Marius M.
A1 Blasczyk, Rainer
A1 Winkler, Martin S.
A1 Nehlmeier, Inga
A1 Kempf, Amy
A1 Hofmann-Winkler, Heike
A1 Hoffmann, Markus
A1 Eiz-Vesper, Britta
A1 Pöhlmann, Stefan
A1 Behrens, Georg M.N.
YR 2021
UL http://medrxiv.org/content/early/2021/04/16/2021.04.16.21255412.abstract
AB Vaccine-induced neutralizing antibodies are key in combating the COVID-19 pandemic. However, delays of boost immunization due to limited availability of vaccines may leave individuals vulnerable to infection and disease for prolonged periods. The emergence of SARS-CoV-2 variants of concern (VOC), B.1.1.7 (United Kingdom), B.1.351 (South Africa) and P.1 (Brazil), may reinforce this issue with the latter two being able to evade control by antibodies. We assessed humoral and T cell responses against SARS-CoV-2 WT and VOC and endemic human coronaviruses (hCoV) that were induced after single and double vaccination with BNT162b2. Despite readily detectable IgG against the receptor-binding domain (RBD) of the SARS-CoV-2 S protein at day 14 after a single vaccination, inhibition of SARS-CoV-2 S-driven host cell entry was weak and particularly low for the B.1.351 variant. Frequencies of SARS-CoV-2 specific T cells were low in many vaccinees after application of a single dose and influenced by immunity against endemic hCoV. The second vaccination significantly boosted T cell frequencies reactive for WT, B.1.1.7 and B.1.351 variants. These results call into question whether neutralizing antibodies significantly contribute to protection against COVID-19 upon single vaccination and suggest that cellular immunity is central for the early defenses against COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00021152Funding StatementThe CoCo Study is supported by unrestricted grants from Novartis, Gilead, Kinderherzen, and Pari. GMNB is supported by German Center for Infection Research, MSW received unrestricted funding from SARTORIUS lung research. This research was funded in part by grants from the state of Lower Saxony (14 - 76103-184 CORONA-12/20) and the Federal Ministry of Health (ZMVI1-2520COR804).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Internal Review Board of Hannover Medical School (MHH, approval number 3639_2017, 8973_BO-K_2020, 9226_BO_K_2020, 9255_BO_K_2020, 9459_BO_K_2020) and University Medicine Goettingen (approval number SeptImmun Study 25/4/19 UE)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request to the corresponding author.